Phase 2 N=33 Durvalumab for MSI-H or POLE Mutated Metastatic Colorectal Cancer
Metastatic Colorectal Cancer
Primary: Objective Response Rates (RECIST 1.1) — 42.4 Percentage of participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=72 Pembrolizumab in MMR-Proficient Metastatic Colorectal Cancer Pharmacologically Primed to Trigger Hypermutation Status
Colorectal Neoplasms · Microsatellite Instability
Primary: Overall Response Rate (ORR) — 0 % of participants
Phase 2 N=124 Study of Pembrolizumab (MK-3475) as Monotherapy in Participants With Previously-Treated Locally Advanced Unresectable or Metastatic Colorectal Cancer (MK-3475-164/KEYNOTE-164)
Colorectal Carcinoma
Primary: Objective Response Rate (ORR) - Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1) Assessed by Central Imaging Vendor — 32.8; 34.9 Percentage of participants
Phase 2 N=21 Study of Binimetinib + Nivolumab Plus or Minus Ipilimumab in Patients With Previously Treated Microsatellite-stable (MSS) Metastatic Colorectal Cancer With RAS Mutation
MSS · RAS-mutant Colorectal Cancer
Primary: Phase 1b: Number of Participants With Dose-Limiting Toxicities (DLT) — 1; 2 Participants
Phase 1 N=82 MEK and MET Inhibition in Colorectal Cancer
Solid Tumor · Colorectal Cancer
Primary: Maximal Tolerated Dose (MTD) of PD-0325901 and PF-02341066 /PF-02341066 or Binimetinib With PF-02341066 — 0; 0; 0; 1 Dose Limiting Toxicities (DLTs)
Phase 2 N=35 A Phase II Trial Assessing Nivolumab in Class II Expressing Microsatellite Stable Colorectal Cancer
Colorectal Cancer
Primary: Durable Clinical Benefit — 3; 32 Participants
Phase 2 N=4 M7824 in Patients With Metastatic Colorectal Cancer or With Advanced Solid Tumors With Microsatellite Instability
Colon Adenocarcinoma · High-Frequency Microsatellite Instability · Metastatic Malignant Solid Neoplasm
Primary: Percentage of Circulating DNA Clearance — 0 percentage of DNA cleared
Phase 2 N=11 TMZ + Olaparib for MGMT Hypermethylated Colorectal Cancer
Colorectal Cancer
Primary: Overall Response Rate — 0; 0; 5; 4 Participants
Phase 2 N=33 Study of Durvalumab and Tremelimumab After Radiation for Microsatellite Stable Metastatic Colorectal Cancer Progressing on Chemotherapy
Colorectal Cancer Metastatic
Primary: Overall Objective Response Rate (ORR) of Dual Immune Checkpoint Blockade by RECIST 1.1 — 9.52 percentage of participants
Phase 2 N=113 Study of MK-3475 in Patients With Microsatellite Unstable (MSI) Tumors (Cohorts A, B and C)
MSI Positive Colorectal Cancer · MSI Negative Colorectal Cancer · MSI Positive Non-Colorectal Cancers
Primary: Immune-related Progression Free Survival (irPFS) at 20 Weeks in MSI Positive and Negative Colorectal Adenocarcinoma Participants Using Immune Related Response Criteria…
Phase 2 N=12 Study of MK-3475 (Pembrolizumab) in Patients With Microsatellite Unstable (MSI) Tumors (Cohort D)
High Tumor Mutation Burden · High TMB (Tumor Mutation Burden) · MSS (Microsatellite Stable)
Primary: Objective Response Rate (ORR) in Patients With MSI (Microsatellite Unstable)-Negative Solid Tumor Malignancies With a Mutator Phenotype — 5 Participants
Phase 2 N=221 Study Evaluating Biomarkers in Patients With Colorectal Cancer and Native KRAS Treated With Chemotherapy + Cetuximab
Colorectal Cancer
Primary: Progression Free Survival — 11.4; 5.9 Months — p=0.004
Phase 3 N=307 Study of Pembrolizumab (MK-3475) vs Standard Therapy in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma (MK-3475-177/KEYNOTE-177)
Colorectal Carcinoma
Primary: Progression-Free Survival (PFS) Per RECIST1.1 As Assessed by Central Imaging Vendor — 16.5; 8.2 Months — p=0.0001
N/A N=239 Educational CD-ROM Compared With Standard Informed Consent for Patients With Colorectal Cancer or a Family History of Colorectal Cancer
Colorectal Cancer · Hereditary Non-polyposis Colon Cancer
Primary: Impact of Standard Informed Consent vs CD-ROM Educational Intervention on Knowledge About Microsatellite Instability (MSI) Testing — 4.07; 4.17 units on a scale
Phase 2 N=6 MoLiMoR - A Study With FOLFIRI-based First-line Therapy With or Without Intermittent Cetuximab
Adenocarcinoma of the Colon · Adenocarcinoma of the Rectum
Primary: Progression Free Survival (PFS) — 0; 0 Participants
Phase 2 N=76 METIMMOX: Colorectal Cancer METastasis - Shaping Anti-tumor IMMunity by OXaliplatin
Colorectal Cancer Metastatic
Primary: Primary - Progression-free Survival (PFS) — 9.2; 9.2 Months of progression-free survival
Phase 1 N=20 Combined PD-1 and CCR5 Inhibition for the Treatment of Refractory Microsatellite Stable mCRC
Metastatic Colorectal Cancer · MSS
Primary: Feasibility Rate of a Combined Therapy — 18 Participants
Phase 2 N=29 Nivolumab and Metformin in Patients With Treatment Refractory MSS Colorectal Cancer
Colorectal Adenocarcinoma · Metastatic Microsatellite Stable Colorectal Carcinoma · Refractory Colorectal Carcinoma
Primary: Overall Response Rate (ORR) — 2; 16 Participants
Phase 2 N=29 Study of Durvalumab (MEDI4736) (Anti-PD-L1) and Trametinib (MEKi) in MSS Metastatic Colon Cancer
Malignant Neoplasms of Digestive Organs · Colorectal Cancer · Colon Cancer
Primary: Immune-related Best Overall Response Rate. — 1 Participants
Phase 2 N=70 Study on the Effectiveness and Safety of the Combination of the Two Drugs Regorafenib and Nivolumab in Patients With Colorectal Cancer (Cancer of the Colon or Rectum Classified as Proficient Mismatch Repair and Microsatellite Stable)
Colorectal Cancer
Primary: Overall Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumours (RECIST) v1.1 Assessed by Investigator — 7.1 percentage (%) of participants — p=0.2721
Phase 2 N=70 Cetuximab in Refractory Colorectal Cancer With K-RAS Mutated and Favorable FcγRIIa (CD32) Genotype
Colorectal Neoplasms
Primary: Overall Survival (OS) Time — 6.71 Months
Phase 2 N=39 Study of PI3Kinase Inhibition (Copanlisib) and Anti-PD-1 Antibody Nivolumab in Relapsed/Refractory Solid Tumors With Expansions in Mismatch-repair Proficient (MSS) Colorectal Cancer
Unresectable or Metastatic Microsatellite Stable (MSS) Solid Tumor · Microsatellite Stable (MSS) Colon Cancer
Primary: Number of Participants Experiencing a Dose Limiting Toxicity — 0 Participants
Phase 2 N=20 A Study With Neoadjuvant mFOLFOX7 Plus Cetuximab to Determine the Surgical Conversion Rate for Unresectable Colorectal Cancer With Metastases Confined to the Liver
Metastatic Colorectal Cancer
Primary: The Percentage of Patients Who Had a Curative (R0) Liver Metastasectomy Following Protocol Treatment, i.e., Metastatic Disease That Can be Completely Resected and/or…
Phase 2 N=59 Study of Nivolumab and Relatlimab in Patients With Microsatellite Stable (MSS) Advanced Colorectal Cancer
Microsatellite Stable (MSS) Colorectal Adenocarcinomas · Colorectal Adenocarcinoma
Primary: Objective Response Rate (ORR) — 0; 1; 2 Participants
Phase 2 N=376 Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer (mCRC)
Colorectal Cancer
Primary: Progression-Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 — 10.09; 12.55 months — p=0.0555
Phase 2 N=289 Treatment Based on Molecular Profiling Diagnosis Carcinoma of Unknown Primary Site
Carcinoma
Primary: Overall Survival — 13.43; 7.62 months
Phase 2 N=33 Efficacy and Safety of Olaparib in Pretreated Patients With Measurable Colorectal Cancer, Stratified by Microsatellite Instability (MSI) Status
Colorectal Cancer
Primary: Tumour Response — 0; 0 Percentage of Participants
Phase 2 N=302 Study to Evaluate the Efficacy and Safety of FOLFOX-4 Plus Cetuximab Versus UFOX Plus Cetuximab.
Previously Untreated Metastatic Colorectal Cancer
Primary: Progression-free Survival (PFS) — 6.6; 8.2 months — p=0.0048
Phase 2 N=56 PhII Trial Panitumumab, Nivolumab, Ipilimumab in Kras/Nras/BRAF Wild-type MSS Refractory mCRC
Colon Cancer
Primary: Overall Response Rate — 32 percentage of participants
Phase 2 N=25 A Study to Assess Efficacy of RXC004 +/- Nivolumab in Ring Finger Protein 43 (RNF43) or R-spondin (RSPO) Aberrated, Metastatic, Microsatellite Stable, Colorectal Cancer After Progression on Standard of Care (SOC)
Colorectal Cancer
Primary: RXC004 Monotherapy (Arm A): Disease Control Rate (DCR) Using Each Patient's Best Overall Response (BOR) According to Response Evaluation Criteria in Solid Tumours…